IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Maurice Winn who wrote (1714)	5/29/2000 5:32:00 PM
From: bob zagorin	Read Replies (1) of 1762

Latest biotech report from Salomon Smith Barney's excellent analyst Meirav Chovav has IDEC rated #1 Buy saying "approval for Rituxin in additional indications, expected in second half, should accelerate sales..." Their end-user R sales are $400m for 2000, $625m for 2001 and $875m for 2002. Their earnings estimates are $.95, $1.60, $2.40. Those are some pretty strong growth nos. They also expect Zevalin BLA in Q4. They say its superior to Coulter's Bexxar because since its linked to radioscope, doesn't have penetrating emissions and can be given as outpatient. There's lots more about pipeline etc. but you get the drift.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next